Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Current Leases (2019 - 2026)

Vaxcyte (PCVX) has 7 years of Current Leases data on record, last reported at $6.1 million in Q1 2026.

  • On a quarterly basis, Current Leases fell 0.7% to $6.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.1 million, a 0.7% decrease, with the full-year FY2025 number at $6.1 million, up 3.96% from a year prior.
  • Current Leases reached $6.1 million in Q1 2026 per PCVX's latest filing, down from $6.1 million in the prior quarter.
  • Over the last five years, Current Leases for PCVX hit a ceiling of $9.6 million in Q3 2024 and a floor of $5.8 million in Q3 2025.
  • A 5-year average of $6.5 million and a median of $6.1 million in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: surged 948.29% in 2022, then plummeted 40.12% in 2025.
  • Tracing PCVX's Current Leases over 5 years: stood at $5.9 million in 2022, then grew by 20.36% to $7.1 million in 2023, then decreased by 17.18% to $5.9 million in 2024, then grew by 3.96% to $6.1 million in 2025, then dropped by 0.64% to $6.1 million in 2026.
  • Business Quant data shows Current Leases for PCVX at $6.1 million in Q1 2026, $6.1 million in Q4 2025, and $5.8 million in Q3 2025.